20 patients with peptic
gastric ulcer and 30 patients with peptic
duodenal ulcer were treated with
Milid (Proglumid). The following results were achieved: in 85% of the patients with peptic
gastric ulcer and in 93% of the patients with
duodenal ulcer the
pain was relieved on the 4th day on the average. In 95-96% of the patients treated the dyspeptic complaints disappeared on the 2-3 day. The endoscopic examination performed on the 20th day revealed full epithelization of the
ulcer in 30% of the patients with
gastric ulcer and in 43.3% of the patients with
duodenal ulcer. Following the treatment course the basic secretion and
acid production fell statistically significantly in the patients with
gastric ulcer while in the patients with
duodenal ulcer the basic and stimulated secretion and
acid production were suppressed. The
drug Milid does not change the serum
gastrin level but suppresses the
gastrin secretion in the gastric juice. The
Milid treatment leads to an increase of the quantity of the
N-acetylneuraminic acid in the gastric juice which partly reflects the cytoprotective action of
Milid. The
drug can be used in the everyday practice for the treatment of
peptic ulcer.